Close Menu

NEW YORK (GenomeWeb) – Illumina and Chinese clinical testing firm KingMed Diagnostics have partnered to develop next-generation sequencing-based oncology and hereditary disease diagnostics for the Chinese market.

Under the agreement, the companies will codevelop an NGS system based on Illumina's MiniSeq technology and KingMed's library prep kits and analysis.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.


Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Sponsored by

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 


This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.